-+ 0.00%
-+ 0.00%
-+ 0.00%

Eupraxia to present new RESOLVE Phase 1b/2 EP-104GI data in eosinophilic esophagitis at ACG, UEG meetings

PUBT·10/09/2026 12:01:15
Listen to the news
Eupraxia to present new RESOLVE Phase 1b/2 EP-104GI data in eosinophilic esophagitis at ACG, UEG meetings
  • Eupraxia Pharmaceuticals outlined upcoming presentations from its RESOLVE Phase 1b/2 trial of EP-104GI in eosinophilic esophagitis.
  • Findings have not been fully disclosed yet; updated analyses are scheduled for ACG on Oct. 12, 2026, then UEG on Oct. 18-19, 2026.
  • Abstracts indicate swallowing symptoms improved and the benefit persisted through a year during dose escalation following a single treatment.
  • Separate UEG data are set to describe improved tissue-level disease features following one administration during dose escalation.
  • The randomized Phase 2b portion is recruiting; interim data are expected in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090800PRIMZONEFULLFEED9842618) on October 09, 2026, and is solely responsible for the information contained therein.